The immunotherapies aiming at PD-1 and CTLA-4 have been applied for CRC [56], prostate cancer [57], lung cancer [58], gastric cancer [59], etc. TIM-3 (HAVCR2), which inhibited tumor immunity with depletion of T cells, was a negative regulation immune check point. This evidence concerns the gene HAVCR2 and lung carcinoma.